Steve Ellul - Biodexa Pharmaceticals Chief Officer
| BDRX Stock | 4.40 0.55 14.29% |
Executive
Steve Ellul is Chief Officer of Biodexa Pharmaceticals
| Address | 1 Caspian Point, Cardiff, United Kingdom, CF10 4DQ |
| Phone | 44 29 2048 0180 |
| Web | https://www.biodexapharma.com |
Biodexa Pharmaceticals Management Efficiency
The company has return on total asset (ROA) of (0.3752) % which means that it has lost $0.3752 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9723) %, meaning that it created substantial loss on money invested by shareholders. Biodexa Pharmaceticals' management efficiency ratios could be used to measure how well Biodexa Pharmaceticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.98 in 2024. Return On Capital Employed is likely to rise to -1.53 in 2024. At this time, Biodexa Pharmaceticals' Total Assets are fairly stable compared to the past year. Other Assets is likely to rise to about 3.2 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 3.3 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Javier Alvarez | Tenaris SA ADR | 57 | |
| Renato Catallini | Tenaris SA ADR | 58 | |
| Gabriel Casanova | Tenaris SA ADR | 65 | |
| Pablo Panizza | Anheuser Busch Inbev | 49 | |
| B Mgt | Transocean | 49 | |
| Sandro Thoma | Transocean | N/A | |
| Michael Sabella | Patterson UTI Energy | N/A | |
| Christian Srensen | Scandinavian Tobacco Group | 59 | |
| Lucas Herscovici | Anheuser Busch Inbev | 47 | |
| David Almeida | Anheuser Busch Inbev | 48 | |
| Roddie Mackenzie | Transocean | N/A | |
| Donna Lorenson | Anheuser Busch Inbev | 51 | |
| Tony Milikin | Anheuser Busch Inbev | 59 | |
| Brady JD | Transocean | 51 | |
| Paola Mazzoleni | Tenaris SA ADR | 43 | |
| Torben Sand | Scandinavian Tobacco Group | N/A | |
| Robert Vayda | Transocean | N/A | |
| Marty Unrein | Patterson UTI Energy | N/A | |
| Yolanda Goettsch | Vita Coco | N/A | |
| David Keddington | Transocean | N/A | |
| Kenneth Pucheu | Patterson UTI Energy | 46 | |
Management Performance
| Return On Equity | -0.97 | ||||
| Return On Asset | -0.38 |
Biodexa Pharmaceticals Leadership Team
Elected by the shareholders, the Biodexa Pharmaceticals' board of directors comprises two types of representatives: Biodexa Pharmaceticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biodexa. The board's role is to monitor Biodexa Pharmaceticals' management team and ensure that shareholders' interests are well served. Biodexa Pharmaceticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biodexa Pharmaceticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dmitry MD, Chief Officer | ||
| Daniel MBA, Vice Technology | ||
| Stephen Stamp, CFO, CEO | ||
| Nicola Tuckwell, VP Operations | ||
| Fiona Sharp, Group Controller | ||
| Steve Ellul, Chief Officer |
Biodexa Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biodexa Pharmaceticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.97 | ||||
| Return On Asset | -0.38 | ||||
| Operating Margin | (79.31) % | ||||
| Current Valuation | (3.36 M) | ||||
| Shares Outstanding | 580.84 K | ||||
| Shares Owned By Insiders | 10.16 % | ||||
| Shares Owned By Institutions | 39.82 % | ||||
| Number Of Shares Shorted | 13.76 K | ||||
| Price To Book | 0.23 X | ||||
| Price To Sales | 30.79 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Biodexa Stock Analysis
When running Biodexa Pharmaceticals' price analysis, check to measure Biodexa Pharmaceticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biodexa Pharmaceticals is operating at the current time. Most of Biodexa Pharmaceticals' value examination focuses on studying past and present price action to predict the probability of Biodexa Pharmaceticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biodexa Pharmaceticals' price. Additionally, you may evaluate how the addition of Biodexa Pharmaceticals to your portfolios can decrease your overall portfolio volatility.